Drug Watch

The latest on the biggest pipeline moves.

What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.

In this video, Peter Lio, MD, FAAD, expands on his presentation at the 19th annual Winter Clinical Dermatology Conference by diving into molluscum contagiousum treatment and the potential of cantharidin 0.7% (VP-102; Verrica).

Vial launches Vial Dermatology contract research organization (CRO) and highlights how it could improve the speed and quality of clinical trials.

The new year promises to be rich with dermatology game changers following a sluggish 2021 for breakthroughs and FDA approvals.

Skin sensitivity will be a factor in vehicles for new treatments.

Click here to answer this week's poll.

The past year gave dermatologists ample cause for both celebration and frustration as they looked forward to new drugs, devices, and technology to optimize patient care. Here, Dermatology Times® editorial advisory board members weigh in on the good, bad, and still-TBD changes that shaped the specialty during 2021.

Verrica Pharmaceuticals announced the FDA acceptance of the New Drug Application (NDA) resubmission for VP-102 (Verrica Pharmaceuticals) for the treatment of molluscum contagiosum.

The FDA grants Priority Review for spesolimab (BI655130; Boehringer Ingelheim) as a treatment for generalized pustular psoriasis.

The FDA approves upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active psoriatic arthritis.